HARBOUR BIOMED
Edit

HARBOUR BIOMED

http://www.harbourbiomed.com/
Last activity: 09.09.2026
Active
Categories: AntibodiesBiotechImmunologyOncologyPharmaceuticals
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on oncology and immunology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions.

The Company’s proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies.


For more information, please visit www.harbourbiomed.com
Followers
1.97K
Mentions
143
Location: China
Employees: 201-500
Total raised: $262.89M
Founded date: 2016
LinkedIn
Email

Investors 1

Funding Rounds 3

DateSeriesAmountInvestors
10.07.2020Series C$102.8M-
13.03.2020Series B$75.09M-
27.08.2018Series B$85M-

Mentions in press and media 143

DateTitleDescription
13.09.2026Breakthrough Asthma Therapy: WIN378 Advances to Phase 3 with Promising Twice-Yearly DosingNew asthma treatment WIN378 delivers strong Phase 2 results. This ultra-long-acting TSLP inhibitor, developed by Kelun-Biotech and Harbour BioMed, and advanced by Windward Bio, significantly improved lung function (FEV1) and reduced key inf...
09.09.2026Venture Capital & Startup Funding Roundup, September 9, 2026: Coatue, Andreessen Horowitz, Greylock, Kleiner Perkins, Sequoia & MoreVenture capital’s center of gravity today isn’t in one neat category called AI. It is moving toward companies that control high-value workflows: legal work, sales, wealth management, cybersecurity, industrial production and even weather-ris...
09.09.2026Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology TherapyPorustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer Phase 2 trial of porustobart for colon cancer ...
08.09.2026HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 StudyThe POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consisten...
08.09.2026Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 StudyThe POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consisten...
27.08.2026Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive DirectorsCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ther...
27.08.2026Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based StrategyCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 27, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of ...
26.08.2026Genetically Modified Mice Market to Reach USD 2.74 Billion by 2030The global Genetically modified mice Market is projected to grow from USD 1.70 billion in 2025 to USD 2.74 billion by 2030, registering a CAGR of 10.0% during the forecast period. Market growth is being driven by the increasing use of mice ...
18.08.2026Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid TumorsCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody ther...
06.08.2026Harbour BioMed Appoints Dr. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative TherapiesCAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 6, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, on...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In